Skip to content

CIK 0001327273

LYRA Lyra Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing May 15, 2026. Close $0.19 on Oct 9, 2026, +47400% from the 52-week low and -98% from the high.

Lyra Therapeutics, Inc. (LYRA) has 20 SEC Form 4 filings on file from 8 insiders, the latest filed on May 15, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

6 open-market trades have been scored at LYRA. The newest: Jason Cavalier (Chief Financial Officer) sold $2,587 of stock on Jan 6, 2026, filed Jan 8, 2026, scored 10 (weak), under a 10b5-1 plan. The largest of the 6 shown: Perceptive Advisors LLC (10% owner) sold $344k on Nov 6, 2025, scored 37 (weak). 2 insiders sold within 14 days of each other around Jan 6, 2026.

LYRA closed at $0.19 on Oct 9, 2026, 47400% above its 52-week low and 98% below its 52-week high.

6 Form 144 notices of planned sales are on file, the latest filed Jan 27, 2026.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company

Price and insider trades, last year

LYRAOct 9, 2026 · close 0.19

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Lyra Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
10WeakJason Cavalier
Chief Financial Officer
sell
$2,587
769 shares
-0%+17% from low-88% from high
13WeakMaria Palasis
President & CEO
sell
$5,726
1,702 shares
-0%+17% from low-88% from high
34WeakPerceptive Advisors LLC
owner
sell
$183k
45,875 shares
-28%-
37WeakPerceptive Advisors LLC
owner
sell
$344k
70,390 shares
-31%-
10WeakJason Cavalier
Chief Financial Officer
sell
$6,094
684 shares
-0%-
13WeakMaria Palasis
President & CEO
sell
$14k
1,565 shares
-0%-

Planned sales

Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales

FiledSellerSharesValueSale datePast 3 months
Jan 27, 2026 Palasis Maria
Officer, Director
1,895
0.11% of outstanding
$3,248Jan 27, 2026$5,725
Jan 6, 2026 Palasis Maria
Officer, Director
1,702
0.10% of outstanding
$5,725Jan 6, 2026$3,881
Oct 14, 2025 Palasis Maria
Officer, Director
537
0.03% of outstanding
$3,881Oct 14, 2025none
Jul 10, 2025 Palasis Maria
Officer, Director
1,565
0.00% of outstanding
$14kJul 10, 2025none
Apr 25, 2025 Waksal Harlan
Officer, Director
145,370
0.22% of outstanding
$15kApr 25, 2025none
Apr 9, 2025 Palasis Maria
Officer, Director
39,567
0.06% of outstanding
$3,545Apr 9, 2025none

Transactions

Every row filed, 29 in all.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
May 14, 2026W Bradford Smith
director
DDisposition to issuer
Common Stock
-640$0.00$00May 15, 2026
Apr 1, 2026Jason Cavalier
Principal Financial Officer
DDisposition to issuer
Common Stock
-667$0.00$0517,880Apr 3, 2026
Apr 1, 2026Maria Palasis
Principal Executive Officer
DDisposition to issuer
Common Stock10b5-1
-2,000$0.00$01,094,733Apr 3, 2026
Jan 6, 2026Jason Cavalier
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-769$3.36$2,587518,547Jan 8, 2026
Jan 6, 2026Maria Palasis
President & CEO
SOpen-market sale
Common Stock10b5-1
-1,702$3.36$5,7261,096,733Jan 8, 2026
Nov 11, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-4,783$4.31$21k161,318Nov 13, 2025
Nov 11, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-537$4.31$2,31718,122Nov 13, 2025
Nov 12, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-7,862$4.06$32k153,456Nov 13, 2025
Nov 12, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-883$4.06$3,58417,239Nov 13, 2025
Nov 13, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-28,597$3.90$112k124,859Nov 13, 2025
Nov 13, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-3,213$3.90$13k14,026Nov 13, 2025
Nov 6, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-28,902$5.18$150k200,480Nov 10, 2025
Nov 6, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-3,247$5.18$17k22,521Nov 10, 2025
Nov 7, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-17,746$4.75$84k182,734Nov 10, 2025
Nov 7, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-1,993$4.75$9,46020,528Nov 10, 2025
Nov 10, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-16,633$4.54$76k166,101Nov 10, 2025
Nov 10, 2025Perceptive Advisors LLC
owner
SOpen-market sale
Common Stockindirect: See Footnotes
-1,869$4.54$8,48518,659Nov 10, 2025
Oct 1, 2025Maria Palasis
President & CEO
AGrant or award
Employee Stock Option (right to buy)derivative
+3,667$0.00$07,333Oct 3, 2025
Jul 10, 2025Jason Cavalier
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-684$8.91$6,094519,316Jul 14, 2025
Jul 10, 2025Maria Palasis
President & CEO
SOpen-market sale
Common Stock10b5-1
-1,565$8.91$14k1,098,435Jul 14, 2025
May 14, 2025W Bradford Smith
director
AGrant or award
Restricted Stock Unitsderivative
+32,000$0.00$032,000May 16, 2025
May 14, 2025nancy lynn snyderman MD
director
AGrant or award
Restricted Stock Unitsderivative
+32,000$0.00$032,000May 16, 2025
May 14, 2025James R Tobin
director
AGrant or award
Restricted Stock Unitsderivative
+32,000$0.00$032,000May 16, 2025
May 14, 2025C Ann Merrifield
director
AGrant or award
Restricted Stock Unitsderivative
+32,000$0.00$032,000May 16, 2025
Jan 8, 2025Jason Cavalier
Chief Financial Officer
AGrant or award
Common Stock
+420,000$0.00$0520,000Jan 10, 2025
Dec 9, 2024Harlan Waksal
Executive Chair
AGrant or award
Performance-based Restricted Stock Unitsderivative
-128,333$0.00$00Dec 11, 2024
Dec 9, 2024Maria Palasis
President & CEO
AGrant or award
Employee Stock Option (right to buy)derivative
+183,333$0.00$0183,333Dec 11, 2024
Oct 16, 2024Jason Cavalier
Chief Financial Officer
AGrant or award
Common Stock
+100,000$0.00$0100,000Oct 18, 2024
Oct 16, 2024Maria Palasis
President & CEO
AGrant or award
Common Stock
+300,000$0.00$0300,000Oct 18, 2024

Insiders

Everyone who has filed a Form 4 here.

Questions about LYRA

Answered from the filings on this page, as of the latest one.

Are insiders buying LYRA?

No. In the last 90 days no insider at Lyra Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade LYRA on the open market?

Jason Cavalier (Chief Financial Officer) sold $2,587 of LYRA on Jan 6, 2026 and filed the Form 4 on Jan 8, 2026. InsiderTell scored 10 (weak), under a 10b5-1 plan, with 2 insiders on the same side within 14 days.

How many insiders file Form 4 at Lyra Therapeutics, Inc.?

8 people have filed a Form 4 at Lyra Therapeutics, Inc., among them Jason Cavalier (Principal Financial Officer), C Ann Merrifield (director), Perceptive Advisors LLC (director and 10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

LYRA insider trading: Lyra Therapeutics, Inc. | InsiderTell